Bristol-Myers Squibb Company announced that the supplemental Biologics License Application for its immuno-oncology drug, Opdivo, has been accepted with priority review by the FDA.
BMS is looking to get Opdivo approved for the treatment of patients with advanced renal cell carcinoma -- kidney cancer -- who have received prior anti-angiogenic therapy.The projected FDA action date is March 16, 2016.
Last month, FDA expanded approved use of Opdivo to advanced lung cancer. Currently, Opdivo is approved for both lung cancer and metastatic melanoma indications.
Read the Zacks press release